Immutep Ltd ADR (IMMP) Stock Price, Quote & News

Company Profile

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 2 8315 7003

Fax: 61 2 8569 1880

Website: www.immutep.com

Address:

Australia Square, Level 32 264 George Street, Sydney, Australia

Roaring_Capybara Aug. 19 at 9:15 AM

$GOSS $IMMP $CAPR @Coco63 IMMP is failed penny-stock garbage. Likely a short-worthy stock as its headed towards a reverse split. 🤣🤣🤣🤡🤡🤡

1 · Reply

Coco63 Aug. 19 at 8:24 AM

$GOSS --> $IMMP is set to take off this weekend ahead of the pipeline update scheduled for next week. $CAPR is going to close the gap at $4, so in the meantime, go for IMMUTEP.

0 · Reply

Coco63 Aug. 18 at 4:10 PM

$CAPR It will come back to close the gap before starting a new leg up. In the meantime, I’m moving into $IMMP, which has a major catalyst next week with the pipeline update.

0 · Reply

Coco63 Aug. 18 at 2:51 PM

$IMMP It would be perfect with some volume. $CAPR

0 · Reply

Coco63 Aug. 18 at 2:19 PM

$IMMP annuel report and update pipeline next week 🚀--> $IMMP $CAPR

0 · Reply

Coco63 Aug. 18 at 2:14 PM

$IMMP Let's go !!! immutep $CAPR

1 · Reply

Coco63 Aug. 18 at 1:35 PM

$IMMP

0 · Reply

rispi Aug. 17 at 8:36 PM

$IMMP where's the big Italian pumper?? Shame on you

0 · Reply

Coco63 Aug. 17 at 12:40 PM

$CAPR Let's go to $IMMP Annual results next week and $MRK possible buyout.

1 · Reply

Coco63 Aug. 17 at 12:24 PM

$IMMP The probability of a buyout by Merck is between 40% and 60%. The purchase price would likely range from €1.5 billion to €2 billion. I’m placing my bets for the end of the year. Immutep’s annual report, due next week, will provide an opportunity to update the status of ongoing clinical trials, and the stock could see a strong upward surge. $MRK $CAPR $GOSS $KPTI $MREO $NVO $LLY $NBIS $FAMI $DFSC $SPCX $XPON $SRPT $AAOI $AMZN $GYGY $NVDA $AAPL $IPST

1 · Reply